D. M A J . Otín
Experto en Salud Auditiva
Complemento mi actividad profesional con mi pasión por la docencia, la divulgación médica, científica e investigación en el síntoma del tínnitus (acúfenos) a través de este blog , donde espero que encontréis información útil, y siempre con mi disposición personal de ayuda, consejo, orientación independiente para todas las personas que tenemos acúfenos.
Consultor tratamiento diferencial en tínnitus (acúfenos)
La integración en su formación de las disciplinas de psicología, educación y medicina, entre otras, hacen del counseling una profesión única que permite a los profesionales usar un abordaje multidimensional que atiende holísticamente (integralmente) las necesidades de los pacientes y la formación continua de los profesionales del área de salud en el campo del síntoma de los acúfenos.
El counseling es una profesión de las ciencias de la salud con plena autonomía y caracterizada por su propio cuerpo de conocimientos, experiencia y práctica profesional.
Para continuar con nuestro trabajo de información y ayuda, Mantener este espacio libre de publicidad y como página independiente en la red. Solicitamos tu colaboración a través de una donación. Ayúdanos a Ayudar.Gracias.
El blog tiene la intención de poder ser de ayuda a todas las personas con acúfenos (tínnitus) que están desorientados respecto a su síntoma, informales de las diferentes posibilidades terapéuticas y mantenerles actualizados con las novedades que vayan surgiendo en el campo del acúfeno. El fin es conseguir que todos las personas que presentan un acúfeno severo o incapacitante alcancen unos niveles de habituación que reduzcan drásticamente la intensidad y la molestia de su síntoma para hacerlo menos perceptible. Esta es la razón de nuestro trabajo y del título del blog ACUFENOS LA PUERTA DE LA ESPERANZA. Saludos cordiales. otínylucas
fuentes de consulta
http://www.ototoxicos.com/
www.medicalnewstoday.com y www.medicaldaily.Com.
Bibliografía
Alván
G, Karlsson K K, Hellgren U, and Villén T. Hearing impairment related to plasma
quinine concentration in healthy volunteers. Br J. Clin Pharmacol.1991; 31(4):
409–412.
Claessen
FA, van Boxtel CJ, Perenboom RM, Tange RA, Wetsteijn JC, Kager PA. Quinine
pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian
subjects and in patients with falciparum malaria. Trop Med Int Health. 1998;
3(6):482-9.
Gunawan
CA, Harijanto PN, Nugroho A. Quinine-induced arrhythmia in a patient with
severe malaria. Acta Med Indones. 2007;39(1):27-32.
Gurkov
R, Eshetu T, Miranda IB, Berens-Riha N, Mamo Y, Girma T, Krause E, Schmidt M,
Hempel JM, Löscher T. Ototoxicity of artemether/lumefantrine in the treatment
of falciparum malaria: a randomized trial. Malar J. 2008;7:179.
Phillips-Howard
PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf.
1996;14(3):131-45.
Gunawan
CA, Harijanto PN, Nugroho A. Quinine-induced arrhythmia in a patient with
severe malaria. Acta Med Indones. 2007;39(1):27-32.
Karbwang
J, Davis TM, Looareesuwan S, Molunto P, Bunnag D, White NJ. A comparison of the
pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy
Thai males. Br J Clin Pharmacol. 1993;35(3):265-71
Watanabe
A, Nakamura K, Morita H, Kusano KF, Ohe T. Long QT syndrome. Nippon Rinsho.
2005;63(7):1171-7.
Atas
A, Agca O, Sarac S, Poyraz A, Akyol MU. Investigation
of ototoxic effects of Taxol on a mice model. Int J Pediatr Otorhinolaryngol.
2006;70(5):779-84.
Girardi
FP, Camisa FP Jr, Sangani PK, Parvataneni HK, Khan SN, Grewal H, Sandhy HS.
Sudden sensorineural hearing loss after spinal surgery under general
anesthesia. J Spinal Disord. 2001;14(2):180-3.
Majstorovic
BM, Radulovic RB, Dukic VB, Kastratovic DA, Popovic NP, Gajic MM. Effects of
nitrous oxide on middle ear pressure. Med Pregl. 2007;60(9-10):473-8.
Park
P, Toung JS, Smythe P, Telian SA, La
Marca F. Unilateral
sensorineural hearing loss after spine surgery: Case report and review of the
literature. Surg Neurol. 2006;66(4):415-8; discussion 418-9.
Pau
H, Selvadurai D, Murty GE. Reversible sensorineural hearing loss after
non-otological surgery under general anaesthetic. Postgrad Med J. 2000;76(895):304-6.
Lima
da Costa D, Erre JP, Pehourq F, Aran JM. Aminoglycoside
ototoxicity and the medial efferent system: II. Comparison of acute effects of
different antibiotics. Audiology. 1998;37(3):162-73.
Selimoglu
E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-26.
McKinnon
BJ, Lassen LF. Naproxen-associated sudden sensorineural hearing loss. Mil Med.
1998;163(11):792-3.
Gil-Loyzaga
P, Bartolomé V, Vicente-Torres A, Carricondo F. Serotonergic innervation of the
organ of Corti. Acta Otolaryngol. 2000;120(2):128-32.
Marais
J. Cochleotoxicity due to Mianserin hydrochloride. J Laryngol Otol.
1991;105(6):475-6.
Bohnen
JM. Antibiotic therapy for abdominal infection. World J Surg.1998;22(2):152-7.
De
Lalla F. Antimicrobial chemotherapy in the control of surgical infectious
complications. J Chemother. 1999;11(6):440-5.
Di
Piro JT, Fortson NS. Combination antibiotic therapy in the management of
intra-abdominal infection. Am J Surg. 1993;165(2A Suppl):82S-88S.
Iqbal
SM, Murthy JG, Banerjee PK, Vishwanathan KA. Metronidazole ototoxicity--report
of two cases. J Laryngol Otol. 1999;113(4):355-7.
Riggs
LC, Shofner WP, Shan AR, Young MR, Hain TC, Matz GJ. Ototoxicity resulting from
combined administration of metronidazole and gentamicin. Am J Otol.1999;20(4):430-4.
Christenson
BJ, Marjala AR. Two cases of sudden sensorineural hearing loss after methadone
overdose. Ann Pharmacother.
2010;44(1):207-10.
van
Gaalen FA, Compier EA, Fogteloo AJ. Sudden
hearing loss after a methadone overdose. Eur Arch Otorhinolaryngol.
2009;266(5):773-4.
Hessén-Söderman
AC, Bergenius J, Palme IB, Bergqvist Y, Hellgren U. Mefloquine Prophylaxis and
Hearing, Postural Control, and Vestibular Functions. J Travel Med.
1995;2(2):66-69.
Wise
M, Toovey S. Reversible hearing loss in temporal association with
chemoprophylactic mefloquine use. Travel Med Infect Dis. 2007;5(6):385-8.
Yu
D, Ding D, Jiang H, Stolzberg D, Salvi R. Mefloquine Damage Vestibular Hair
Cells in Organotypic Cultures. Neurotox Res. 2010 (en prensa)
Segal
GM, Duckert LG. Reversible mechlorethamine-associated hearing loss in a patient
with Hodgkin's disease. Cancer.
1986;57(6):1089-91.
Guthrie
OW. Aminoglycoside induced ototoxicity. Toxicology.
2008;30;249(2-3):91-6.
Henley
et al. Ototoxicity in developing mammals. Brain Res Brain Res Rev.
1995;20(1):68-90.
Matz
GJ. Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am.
1993;26(5):705-12.
McCracken
GH Jr. Aminoglycoside toxicity in infants and children. Am J Med.
1986;30;80(6B):172-8.
Friedman
RA, House JW, Luxford WM, Gherini S, Mills D. Profound hearing loss associated
with hydrocodone/acetaminophen abuse. Am J Otol. 2000;21(2):188-91.
Ho
T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Physician. 2007;10(3):467-72.
Oh
AK, Ishiyama A, Baloh RW. Deafness associated with abuse of
hydrocodone/acetaminophen. Neurology. 2000; 27;54(12):2345.
Yorgason
JG, Kalinec GM, Luxford WM, Warren FM, Kalinec F. Acetaminophen ototoxicity
after acetaminophen/hydrocodone abuse: evidence from two parallel in vitro
mouse models. Otolaryngol Head Neck Surg. 2010;142(6):814-9, 819.e1-2.
Borkholder
DA. State-of-the-art mechanisms of intracochlear drug delivery. Curr Opin Otolaryngol Head Neck Surg.
2008;16(5):472-7.
Guthrie
OW. Aminoglycoside induced ototoxicity. Toxicology.
2008;30;249(2-3):91-6.
McCall
et al. Drug delivery for treatment of inner ear disease: current state of
knowledge. Ear Hear.
2010;31(2):156-65.
Bauer
CA, Brozoski TJ. Assessing tinnitus and prospective tinnitus therapeutics using
a psychophysical animal model. J Assoc Res Otolaryngol. 2001;2(1):54-64.
Pierce
DA, Holt SR, Reeves-Daniel A. A probable case of gabapentin-related reversible
hearing loss in a patient with acute renal failure. Clin Ther.
2008;30(9):1681-4.
Witsell
DL, Hannley MT, Stinnet S, Tucci DL. Treatment of tinnitus with gabapentin: a
pilot study. Otol Neurotol.
2007;28(1):11-5.
Rybak
LP. Ototoxicity of loop diuretics. Otolaryngol Clin North Am. 1993;26(5):829-44.
Frenay
M, Lebrun C, Lonjon M, Bondiau PY, Chatel M. Up-front chemotherapy with
fotemustine (F) / cisplatin (CDDP) / etoposide (VP16) regimen in the treatment
of 33 non-removable glioblastomas. Eur J Cancer. 2000;36(8):1026-31.
Gocer
C, Eryilmaz A, Kayikci ME, Korkmaz H, Surucu S, Akmansu SH. Functional and
morphological effects of fotemustine on the auditory system of the rat. J Laryngol Otol. 2008;122(6):551-6.
O'Brien
RK, Sparling TG. Gentamicin and fludarabine ototoxicity. Ann Pharmacother.
1995;29(2):200-1.
Barbero
P, Lotersztein V, Bronberg R, Perez M, Alba L: Acitretin embryopathy: a case
report. Birth Defects Res A Clin Mol Teratol. 2004, 70:831-3.
Langer
K, Konrad K, Wolff K. Keratitis, ichthyosis and deafness (KID)-syndrome: report
of three cases and a review of the literature. Br J Dermatol.
1990;122(5):689-97.
Nazzaro
V, Blanchet-Bardon C, Lorette G, Civatte J. Familial occurrence of KID
(keratitis, ichthyosis, deafness) syndrome. Case reports of a mother and
daughter. J Am Acad Dermatol. 1990;23(2
Pt 2):385-8.
Wereide
K. Mutilating palmoplantar keratoderma successfully treated with etretinate.
Acta Derm Venereol. 1984;64(6):566-9.
Conlon
BJ, McSwain SD, SmithDW. Topical gentamicin and ethacrynic acid: effects on
cochlear function. Laryngoscope.
1998 ;108(7):1087-9.
Ding
D, McFadden SL, Woo JM, Salvi RJ. Ethacrynic acid rapidly and selectively
abolishes blood flow in vessels supplying the lateral wall of the cochlea. Hear
Res. 2002;173(1-2):1-9.
Ding
D, McFadden SL, Browne RW, Salvi RJ. Late dosing with ethacrynic acid can
reduce gentamicin concentration in perilymph and protect cochlear hair cells.
Hear Res. 2003;185(1-2):90-6.
Ding
D, Jiang H, Wang P, Salvi R. Cell death after co-administration of cisplatin
and ethacrynic acid. Hear Res. 2007;226(1-2):129-39.
Ding
D, Jiang H, Salvi RJ. Mechanisms of rapid sensory hair-cell death following
co-administration of gentamicin and ethacrynic acid. Hear Res. 2010; 259(1-2):16-23.
Rybak
LP. Ototoxicity of loop diuretics. Otolaryngol Clin North Am. 1993;26(5):829-44.
Peng
AQ, Lu YD, Ren JH, Chen Z. Evaluation of the effect of streptomycin perfusion
of the labyrinth in the treatment of Meniere's disease and endolymphatic
hydrops. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2000;14(10):438-9.
Qian
Y, Guan MX. Interaction of aminoglycosides with human mitochondrial 12S rRNA
carrying the deafness-associated mutation. Antimicrob Agents Chemother.
2009;53(11):4612-8.
Selimoglu
E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-26.
Wang
X, Jia S, Currall B, Yang S, He DZ. Streptomycin and gentamicin have no
immediate effect on outer hair cell electromotility. Hear Res.
2007;234(1-2):52-8.
Christensen
LA, Morehouse CR, Powell TW, Alchediak T, Silio M: Antiviral therapy in a child
with pediatric human immunodeficiency virus (HIV): case study of audiologic
findings. J Am Acad Audiol. 1998; 9(4):292-8.
Marra
CM, Wechkin HA, Longstreth WT Jr, Rees TS, Syapin CL, Gates GA. Hearing loss
and antiretroviral therapy in patients infected with HIV-1. Arch Neurol.
1997;54(4):407-10.
Schouten
JT, Lockhart DW, Rees TS, Collier AC, Marra CM: A prospective study of hearing
changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people.
BMC Infect Dis. 2006; 6:28
Delehaye
E, Capobianco S, Bertetto IB, Meloni F. Distortion-product otoacoustic
emission: early detection in deferoxamine induced ototoxicity. Auris Nasus
Larynx. 2008;35(2):198-202.
Mostafa
BE, Tawfik S, Hefnawi NG, Hassan MA, Ismail FA. The role of deferoxamine in the
prevention of gentamicin ototoxicity: a histological and audiological study in
guinea pigs. Acta Otolaryngol. 2007;127(3):234-9.
Shamsian
BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi S, Esfehani H,
Garallahi F, Amini R. Sensory neural hearing loss in beta-thalassemia major
patients treated with deferoxamine. Pediatr Hematol Oncol. 2008;25(6):502-8.
Gallegos-Castorena
S, Martínez-Avalos A, Mohar-Betancourt A, Guerrero-Avendaño G, Zapata-Tarrés M,
Medina-Sansón A. Toxicity prevention with amifostine in pediatric osteosarcoma
patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol. 2007
Sep;24(6):403-8.
Saito
et al. Cyclosporin A inhibits the extrusion pump function of p-glycoprotein in
the inner ear of mice treated with vinblastine and doxorubicin. Brain Res. 2001;901(1-2):265-70.
Lue
AJ, Zhao HB, Brownell WE. Chlorpromazine alters outer hair cell
electromotility. Otolaryngol Head
Neck Surg. 2001;125(1):71-6.
Oqhalai
JS. Chlorpromazine inhibits cochlear function in guinea pigs. Hear Res. 2004;198(1-2):59-68.
Zheng
J, Deo N, Zou Y, Grosh K, Nuttal AL. Chlorpromazine
alters cochlear mechanics and amplification: in vivo evidence for a role of
stiffness modulation in the organ of corti. J
Neurophysiol. 2007;97(2):994-1004.
Bortoli
R, Santiago M. Chloroquine ototoxicity. Clin Rheumatol. 2007;26(11):1809-10.
Johansen
PB, Gran JT. Ototoxicity due to hydroxychloroquine: report of two cases. Clin
Exp Rheumatol. 1998;16(4):472-4.
Ochsendorf
FR, Runne U. Chloroquine and hydroxychloroquine: side effect profile of
important therapeutic drugs. Hautarzt. 1991;42(3):140-6.
Phillips-Howard
PA, ter Kuile FO. CNS adverse events associated with antimalarial agents. Fact
or fiction? Drug Saf. 1995;12(6):370-83.
Seçkin
U, Ozoran K, Ikinciogullari A, Borman P, Bostan EE. Hydroxychloroquine
ototoxicity in a patient with rheumatoid arthritis. Rheumatol Int. 2000;19(5):203-4.
Federspil
P. Topically induced ototoxicity. HNO. 1984;32(2):81-3.
Igarashi
Y, Suzuki J. Cochlear ototoxicity of chlorhexidine gluconate in cats. Arch
Otorhinolaryngol. 1985;242(2):167-76.
Federspil
P. Topically induced ototoxicity. HNO. 1984;32(2):81-3.
Igarashi
Y, Suzuki J. Cochlear ototoxicity of chlorhexidine gluconate in cats. Arch
Otorhinolaryngol. 1985;242(2):167-76.
Macfadyen
CA, Acuin JM, Gamble C. Systemic antibiotics versus topical treatments for
chronically discharging ears with underlying eardrum perforations. Cochrane
Database Syst Rev. 2006;(1):CD005608.
Abi-Hachem
RN, Zine A, Van De Water TR. The injured cochlea as a target for inflammatory
processes, initiation of cell death pathways and application of related
otoprotectives strategies. Recent Pat CNS Drug Discov. 2010;5(2):147-63.
Al-Khatib
T, Cohen N, Carret AS, Daniel S. Cisplatinum ototoxicity in children, long-term
follow up. Int J Pediatr Otorhinolaryngol. 2010;74(8):913-919.
Dille
MF, Konrad-Martin D, Gallum F, Helt WJ, Gordon JS, Reavis KM et al. Tinnitus
onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a
large prospective study. J Am Acad Audiol. 2010;21(6):409-17.
Hao
S, Jiang X, Yan A, Yang B. Perinatal cisplatin exposure induces cochlear
apoptosis in newborn guinea pigs. Arch Toxicol. 2010 Apr 16. [Epub ahead of
print]
Dean
JB, Hayashi SS, Albert CM, King AA, Karzon R, Havashi RJ. Hearing loss in
pediatric oncology patients receiving carboplatin-containing regimens. J
Pediatr Hematol Oncol. 2008;30(2):130-4.
Dille
MF, Konrad-Martin D, Gallum F, Helt WJ, Gordon JS, Reavis KM et al. Tinnitus
onset rates from chemotherapeutic agents and ototoxic antibiotics: results of a
large prospective study. J Am Acad Audiol. 2010;21(6):409-17.
Grewal
S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late
effects of childhood cancer therapy: a report from the Children's Oncology
Group. Pediatrics. 2010;125(4):e938-50.
Zhou
Y, Ding D, Kraus KS, Yu D, Salvi RJ. Functional
and structural changes in the chinchilla cochlea and vestibular system
following round window application of carboplatin. Audiol Med.
2009;7(4):189-199.
Nekrassov
V, Sitges M. Comparison of acute, chronic and post-treatment effects of
carbamazepine and vinpocetine on hearing loss and seizures induced by
4-aminopyridine. Clin Neurophysiol. 2008;119(11):2608-14.
Savage
J, Cook S, Wadell A. Tinnitus. Clin Evid (Online). 2007; 1;2007. pii: 0506.
Sitges
M, Nekrassov V. Acute and chronic effects of carbamazepine, phenytoin,
valproate and vinpocetine on BAEP parameters and threshold in the guinea pig.
Clin Neurophysiol. 2007;118(2):420-6.
Duggal
P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis
patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose
Throat Disord. 2007 Nov 12;7:5.
Holdiness
MR. Neurological manifestations and toxicities of the antituberculosis drugs. A review. Med Toxicol.1987;2(1):33-51.
Mick
P, Westerberg BD. Sensorineural hearing loss as a probable serious adverse drug
reaction associated with low-dose oral azithromycin. J Otolaryngol.
2007;36(5):257-63.
Pawlowsli
KS, Si E, Wright CG, Koulich E, Hosseini K, Roland PS. Ototoxicity of topical
azithromycin solutions in the guinea pig. Arch Otolaryngol Head Neck Surg.
2010;136(5):481-7.
Ress
BD, Gross EM. Irreversible sensorineural hearing loss as a result of
azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol.
2000;109(4):435-7.
Uzun
C, Koten M, Adali MK, Yorulmaz F, Yagiz R, Karasalihoglu AR. Reversible
ototoxic effect of azithromycin and clarithromycin on transiently evoked
otoacoustic emissions in guinea pigs. J
Laryngol Otol. 2001;115(8):622-8.
Mick
P, Westerberg BD. Sensorineural hearing loss as a probable serious adverse drug
reaction associated with low-dose oral azithromycin. J Otolaryngol.
2007;36(5):257-63.
Pawlowsli
KS, Si E, Wright CG, Koulich E, Hosseini K, Roland PS. Ototoxicity of topical
azithromycin solutions in the guinea pig. Arch Otolaryngol Head Neck Surg.
2010;136(5):481-7.
Ress
BD, Gross EM. Irreversible sensorineural hearing loss as a result of
azithromycin ototoxicity. A case report. Ann Otol Rhinol Laryngol.
2000;109(4):435-7.
Uzun
C, Koten M, Adali MK, Yorulmaz F, Yagiz R, Karasalihoglu AR. Reversible
ototoxic effect of azithromycin and clarithromycin on transiently evoked
otoacoustic emissions in guinea pigs. J
Laryngol Otol. 2001;115(8):622-8.
Lima
da Costa D, Erre JP, Pehourq F, Aran JM. Aminoglycoside
ototoxicity and the medial efferent system: II. Comparison of acute effects of
different antibiotics. Audiology. 1998;37(3):162-73.
Selimoglu
E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-26.
Mahasitthiwat
V. A woman with sudden bilateral sensorineural hearing loss after treatment
psoriasis with acitretin. J Med Assoc Thai. 2005;88 Suppl 1:S79-81.
Sahoo
B, Handa S, Kaur I, Radotra BD, Kumar B. KID syndrome: response to acitretin. J
Dermatol. 2002;29(8):499-502.
Bektas
D, Martin GK, Stagner BB, Lonsbury-Martin BL. Noise-induced hearing loss in
mice treated with antiretroviral drugs. Hear Res. 2008;239(1-2):69-78. Epub
2008; 8.
Schouten
JT, Lockhart DW, Rees TS, Collier AC, Marra CM: A prospective study of hearing
changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve
people. BMC Infect Dis. 2006; 6:28
Bokemeyer
C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L.
Analysis of risk factors for cisplatin-induced ototoxicity in patients with
testicular cancer. Br J Cancer. 1998 77(8): 1355–1362.
Dearnaley
DP, Fossa SD, Kaye SB, Cullen MH, Harland SJ, Sokal MP, Graham JD, Roberts JT,
Mead GM, Williams MV, Cook PA, Stenning SP. Adjuvant bleomycin, vincristine and
cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a
prospective trial (MRC TE17). Br J Cancer. 2005 20;92(12):2107-13.
Earl
HM, Connolly S, Latoufis C, Eagle K, Ash CM, Fowler C, Souhami RL. Long-term
neurotoxicity of chemotherapy in adolescents and young adults treated for bone
and soft tissue sarcomas. Sarcoma.
1998;2(2):97-105.
Hunt
KJ, Longton G, Williams MA, Livingston RB. Treatment of malignant mesothelioma
with methotrexate and vinblastine, with or without platinum chemotherapy. Chest 1996;109(5):1239-42.
Elloumi
H, Houissa F, Hadj NB, Gargouri D, Romani M, Kharrat J, Ghorbel A. Sudden
hearing loss associated with peginterferon and ribavirin combination therapy
during hepatitis C treatment. World J Gastroenterol. 2007; 28;13(40):5411-2.
Shin
MK, Kim TH, Ju K, Ha CY, Min HJ, Jung WT, Lee OJ. A case of sudden-onset
hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for
chronic hepatitis C. Korean J Hepatol. 2009;15(3):370-4.
Wong
VK, Cheong-Lee C, Ford JA, Yoshida EM. Acute sensorineural hearing loss
associated with peginterferon and ribavirin combination therapy during hepatitis
C treatment: outcome after resumption of therapy. World J Gastroenterol. 2005;
14;11(34):5392-3.
Bibliografía
Kakehata
S, Santos-Sacchi J. Effects of salicylate and lanthanides on outer hair cell
motility and associated gating charge. J Neurosci. 1996; 15;16(16):4881-9.
Kornhauser
A, Wei RR, Yamaguchi Y, Coelho SG, Kaidbey K, Barton C, Takahashi K, Beer JZ,
Miller SA, Hearing VJ. The effects of topically applied glycolic acid and
salicylic acid on ultraviolet radiation-induced erythema, DNA damage and
sunburn cell formation in human skin. J Dermatol Sci. 2009;55(1):10-7.
Morimoto
N, Raphael RM, Nygren A, Brownell WE. Excess plasma membrane and effects of
ionic amphipaths on mechanics of outer hair cell lateral wall. Am J Physiol
Cell Physiol. 2002;282(5):C1076-86.
Song
Y, Guallar V, Baker NA. Molecular dynamics simulations of salicylate effects on
the micro- and mesoscopic properties of a dipalmitoylphosphatidylcholine
bilayer. Biochemistry. 2005
18;44(41):13425-38.
Hong
BN, Yi TH, Kim SY, Kang TH. High dosage sildenafil induces hearing impairment
in mice. Biol Pharm Bull.
2008;31(10):1981-4.
McGwin
G Jr. Phosphodiesterase type 5 inhibitor use and hearing impairment. Arch
Otolaryngol Head Neck Surg. 2010;136(5):488-92.
Snodgrass
AJ, Campbell HM, Mace DL, Faria VL, Swanson KM, Holodniy M. Sudden
sensorineural hearing loss associated with vardenafil. Pharmacotherapy. 2010;30(1)
Lima
da Costa D, Erre JP, Pehourq F, Aran JM. Aminoglycoside
ototoxicity and the medial efferent system: II. Comparison of acute effects of
different antibiotics. Audiology. 1998;37(3):162-73.
Selimoglu
E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-26.
Battaglia
A, Carey JC, South ST, Wright TJ. Wolf-Hirschhorn Syndrome. GeneReviews
[Internet]. Seattle (WA):
University of Washington, Seattle; 1993-.2002 Apr 29 [updated 2010 Jun 17].
Cohen
BH, Chinnery PF, Copeland WC. POLG-Related Disorders. GeneReviews [Internet].
Seattle (WA): University of Washington, Seattle; 1993-.2010 Mar 16.
DiMauro
S, Hirano M. MERRF . GeneReviews [Internet]. Seattle (WA): University of
Washington, Seattle; 1993-.2003 Jun 03 [updated 2009 Aug 18].
Hori
A, Kataoka S, Sakai K, Hirose G, Iwasaki N, Horiguchi A, Takashima M, Tomoda K.
Valproic acid-induced hearing loss and tinnitus. Intern Med. 2003
Nov;42(11):1153-4.
Brummett
RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob
Agents Chemother. 1989;33(6):791-6.
uckingham
SC, McCullers JA, Luján-Zilbermann J, Knapp KM, Orman KL, English BK. Early
vancomycin therapy and adverse outcomes in children with pneumococcal
meningitis. Pediatrics. 2006 May;117(5):1688-94.
Forouzesh
A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of
increasing doses. Antimicrob Agents Chemother. 2009;53(2):483-6. Epub 2008; 10.
Nicolosi
L, Langella L, Krzysztofiak A, Ticca F. Streptococcus pneumoniae meningitis in
children. Case records 1985 – 2003. Infez Med 2004 Dec;12(4):252-8.
Shields
RK, Martello JL, Potoski BA. Is vancomycin ototoxicity a significant risk? Antimicrob Agents Chemother. 2009
;53(10):4572; author reply 4572-3.
Poch-Broto
J. Intoxicaciones laberínticas por fármacos. En: El Oído Interno.
Ultraestructura, embriogénesis y algunos aspectos patológicos. En: M. Merchán.
Ed. Ediciones de la Universidad de Salamanca y de la Universidad de Alicante
1983; capítulo 4 :135-148